EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Methylation-based signature to distinguish indolent and aggressive prostate cancer

Muheng Liao, Jace Webster, Amy Ly, Emily Rozycki, Christopher A Maher iD

Biology Open · 2025

DOI: 10.1242/bio.062281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biology Open, 2025. Verfasst von Muheng Liao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PCRP Prostate Cancer Biorepository Network, Washington University in St Louis School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer management faces significant challenges in distinguishing indolent from aggressive disease, particularly since most patients are intermediate-risk and therefore hinders the ability to recommend standardized treatment recommendations. Moreover, current prognostic tools including Gleason scoring and tumor staging demonstrate limited accuracy for predicting disease progression and tumor recurrence. DNA methylation serves as a stable epigenetic modification that directly regulates gene expression, making it an ideal biomarker for cancer prognosis. Therefore, this study leveraged whole-genome enzymatic methylation sequencing on 120 patients to develop a novel prognostic signature for aggressive prostate cancer progression. We analyzed 20,849 differentially methylated regions (DMRs) and employed multiple machine learning approaches to identify optimal biomarkers. This revealed a 14-region DNA methylation signature that can serve as independent prognostic prediction factors outperforming traditional clinical indices. Further, when combined into a risk score it achieved a clinically meaningful odds ratio. This methylation-based approach provides actionable information for treatment decisions and surveillance strategies, representing a significant advancement toward precision medicine in prostate cancer management through biologically informed risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsDNA MethylationBiomarkers, TumorHumansMalePrognosisEpigenesis, GeneticGene Expression Regulation, NeoplasticNeoplasm GradingDisease ProgressionMachine LearningComputational Biology

Stichwörter der Autor:innen

Clinical prognosisDNA methylationEpigenomeMachine learningProstate cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA.
  • Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63108, USA.
  • Department of Biomedical Engineering, Washington University McKelvey School of Engineering, St Louis, MO 63130, USA.

ORCID-Profile: Christopher A Maher

Förderung

  • PCRP Prostate Cancer Biorepository Network
  • Washington University in St Louis School of Medicine

Zitieren

APA

Liao, M., Webster, J., Ly, A., Rozycki, E., & Maher, C. A. (2025). Methylation-based signature to distinguish indolent and aggressive prostate cancer. Biology Open. https://doi.org/10.1242/bio.062281

Vancouver

Liao M, Webster J, Ly A, Rozycki E, Maher CA. Methylation-based signature to distinguish indolent and aggressive prostate cancer. Biology Open. 2025. doi:10.1242/bio.062281

BibTeX
@article{Liao2025,
  author = {Liao, Muheng and Webster, Jace and Ly, Amy and Rozycki, Emily and Maher, Christopher A},
  title = {Methylation-based signature to distinguish indolent and aggressive prostate cancer},
  journal = {Biology Open},
  year = {2025},
  doi = {10.1242/bio.062281}
}
Kostenlos starten →